For social and economic reasons, glaucoma screening is a useful and necessary task, with possible benefits for individuals and the health care system arising from the early diagnosis and early therapy of patients with glaucoma. Early treatment of patients with glaucoma decreases the probability that those patients will become blind and lowers the direct and indirect costs for patients with glaucoma. Most of the reported studies dealing with glaucoma screening used only one parameter (eg, intraocular pressure) to detect and to discriminate glaucoma patients from healthy subjects. Glaucoma screening devices might be combined to obtain the best specificity and sensitivity. Because the diagnosis of glaucoma is very closely associated with a morphologic change in the optic nerve head, one screening parameter should be the morphology of the papilla. To increase specificity and sensitivity, a combination of morphologic and functional testing might be useful. In this review, we report the context of glaucoma screening in terms of health economics, the testing quality of devices for functional and morphologic screening, and the results of a pilot study.